Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, forecasts that Eli Lilly's ruboxistaurin, the first disease-modifying agent for use in distal symmetrical polyneuropathy (DSP), will dominate the diabetic neuropathy drug market. Ruboxistaurin will attain nearly two-thirds of market share by 2011, according to a new Pharmacor report entitled Diabetic Neuropathy.

(Photo: http://www.newscom.com/cgi-bin/prnh/20000303/DECISION )

"The introduction of ruboxistaurin marks the debut of a disease-modifying agent on the distal symmetrical polyneuropathy (DSP) market in the United States and Europe," said Bornadata Evans Bain, Ph.D., analyst at Decision Resources. "The drug's entry will drive the growth of the DSP market from $350 million in 2001 to $1.34 billion in 2011 in the major markets (United States, France, Germany, Italy, Spain, United Kingdom, and Japan)."

Disease Background-Diabetic Neuropathy

Diabetic neuropathy is a demonstrable neurological disorder in which nerve damage occurs as a result of chronically high levels of glucose in the blood. The most common clinical manifestation of diabetic neuropathy is DSP, a neuropathy affecting both sides of the body and attacking the distal sensory nerves. This neuropathy initially affects the lower extremities but later can move to the upper extremities. It accounts for approximately 80-85% of all neuropathy observed in diabetic patients.

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies based on primary and secondary research conducted by Decision Resources' on-staff experts. Each comprehensive study assesses a host of market-impacting factors and analyzes the commercial outlook for drugs in research and development. Cardium, Cognos, Immune and Inflammatory Disorders, Infectious Disease, Metabolic Disorders, Psychiatric Disorders, and Onkos concentrate on specific therapeutic areas. Mosaic covers high-interest disease states. Diabetic Neuropathy is a Metabolic Disorders report.

About Decision Resources

Decision Resources, Inc., is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. The company provides strategic information services and assesses international pharmaceutical and health care industry trends. Visit Decision Resources at www.decisionresources.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall    Decision Resources, Inc.    781-296-2563    emarshall@dresources.com 

MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X86552669

Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20000303/DECISION

AP Archive: http://photoarchive.ap.org/

PRN Photo Desk, 888-776-6555 or 212-782-2840

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall for Decision Resources, Inc., +1-781-296-
2563, emarshall@dresources.com

New Report Finds That Total HMO Enrollment Decreases In Metropolitan Areas

View Now